Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.2 (
acetyl-CoA carboxylase
)
2,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cutaneous melanoma is the most life-threatening neoplasm of the skin, accounting for most of the skin cancer deaths. Accumulating evidence suggests that targeting metabolism is an appealing strategy for melanoma therapy. Mitochondrial NAD(P)(+)-dependent malic enzyme (
ME2
), an oxidative decarboxylase, was evaluated for its biological significance in cutaneous melanoma progression.
ME2
mRNA and protein expression significantly increased during melanoma progression, as evidenced by Gene Expression Omnibus analysis and immunohistochemistry on clinically annotated tissue microarrays, respectively. In addition,
ME2
knockdown attenuated melanoma cell proliferation in vitro.
ME2
ablation resulted in reduced cellular ATP levels and elevated cellular reactive oxygen species production, which activated the AMP-activated protein kinase pathway and inhibited
acetyl-CoA carboxylase
. Furthermore,
ME2
expression was associated with cell migration and invasion.
ME2
knockdown decreased anchorage-independent growth in vitro and tumor cell growth in vivo. These results suggested that
ME2
might be an important factor in melanoma progression and a novel biomarker of invasion.
...
PMID:Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion. 2566 73